Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences

Journal of General Virology

Volumn 86, Issue 9, 2005, Pages 2459-2468

  De la Cruz Hernández, Erick ^a   García Carrancá, Alejandro ^a   Mohar Betancourt, Alejandro ^a   Dueñas González, Alfonso ^a   Contreras Paredes, Adriana ^a   Pérez Cardenas, Enrique ^a   Herrera Goepfert, Roberto ^b   Lizano Soberón, Marcela ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN BAX; PROTEIN E6; PROTEIN P53;

AMERICAN INDIAN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASIAN; CARCINOGENESIS; CLONE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; MOLECULAR MECHANICS; MOUSE; MUTAGENESIS; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY MECHANISM; TUMOR VOLUME;

ANIMALS; CELL LINE; DNA-BINDING PROTEINS; FEMALE; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA SPLICING; UTERINE CERVICAL NEOPLASMS; VARIATION (GENETICS);

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 18; MUS MUSCULUS;

EID: 23844477702     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80945-0     Document Type: Article

References (41)

1. Bernard, H. U., Chan, S. Y., Manos, M. M., Ong, C. K., Villa, L. L., Delius, H., Peyton, C. L., Bauer, H. M. & Wheeler, C. M. (1994). Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 170, 1077-1085.
2. Berumen, J., Ordoñez, R. M., Lazcano, E. & 7 other authors (2001). Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 93, 1325-1330.
3. Bosch, F. X., Lorincz, A., Muñoz, N., Meijer, C. J. L. M. & Shah, K. V. (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55, 244-265.
4. Brow, D. A. (2002). Allosteric cascade of spliceosome activation. Annu Rev Genet 36, 333-360.
5. Burger, R. A., Monk, B. J., Kurosaki, T., Anton-Culver, H., Vasilev, S. A., Berman, M. L. & Wilczynski, S. P. (1996). Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 88, 1361-1368.
6. Caelles, C., Helmberg, A. & Karin, M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220-223.
7. Chakrabarti, O., Veeraraghavalu, K., Tergaonkar, V., Liu, Y., Androphy, E. J., Stanley, M. A. & Krishna, S. (2004). Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by Notch signaling and oncogenic Ras. J Virol 78, 5934-5945.
8. Chen, X., Ko, L. J., Jayaraman, L. & Prives, C. (1996). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10, 2438-2451.
9. Chipuk, J. E. & Green, D. R. (2004). Cytoplasmic p53: Bax and forward. Cell Cycle 3, 429-431.
10. Czegledy, J., Evander, M., Hernadi, Z., Gergely, L. & Wadell, G. (1994). Human papillomavirus type 18 E6* mRNA in primary tumors and pelvic lymph nodes of Hungarian patients with squamous cervical cancer. Int J Cancer 56, 182-186.
11. Dalstein, V., Riethmuller, D., Prétet, J.-L., Le Bail Carval, K., Sautière, J.-L., Carbillet, J.-P., Kantelip, B., Schaal, J.-P. & Mougin, C. (2003). Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 106, 396-403.
12. De Boer, M. A., Peters, L. A. W., Aziz, M. F., Siregar, B., Cornain, S., Vrede, M. A., Jordanova, E. S. & Fleuren, G. J. (2005). Human papillomavirus type 18 variants: histopathology and E6 /E7 polymorphisms in three countries. Int J Cancer 114, 422-425.
13. Di Leonardo, A., Linke, S. P., Clarkin, K. & Wahl, G. M. (1994). DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8, 2540-2551.
14. Halpern, A., McBride, A., Myers, G., Baker, C., Wheeler, C. M. & Doorbar, J. (editor) (1997). Human Papillomaviruses. A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos, NM: Los Alamos National Laboratory.
15. Hecht, J. L., Kadish, A. S., Jiang, G. & Burk, R. D. (1995). Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer 60, 369-376.
16. Hildesheim, A., Schiffman, M., Bromley, C. & 12 other authors (2001). Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 93, 315-318.
17. Im, S. S., Wilczynski, S. P., Burger, R. A. & Monk, B. J. (2003). Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 9, 4145-4150.
18. Kämmer, C., Warthorst, U., Torrez-Martinez, N., Wheeler, C. M. & Pfister, H. (2000). Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. J Gen Virol 81, 1975-1981.
19. Lassus, P., Ferlin, M., Piette, J. & Hibner, U. (1996). Anti-apoptotic activity of low levels of wild-type p53. EMBO J 15, 4566-4573.
20. Lizano, M., Berumen, J., Guido, M. C., Casas, L. & Garcia-Carranca, A. (1997). Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J Natl Cancer Inst 89, 1227-1231.
21. Mantovani, F. & Banks, L. (2001). The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20, 7874-7887.
22. McLachlin, C. M., Tate, J. E., Zitz, J. C., Sheets, E. E. & Crum, C. P. (1994). Human papillomavirus type 18 and intraepithelial lesions of the cervix. Am J Pathol 144, 141-147.
23. Moscicki, A.-B., Hills, N., Shiboski, S. & 9 other authors (2001). Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285, 2995-3002.
24. Myers, G., Bernard, H. U., Delius, H., Favre, J., Icenogle, J., Van Ranst, M. & Wheeler, C. M. (editors) (1994). Human Papillomaviruses. A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos, NM: Los Alamos National Laboratory.
25. Ong, C.-K., Chan, S.-Y., Saveria Campo, M. & 8 other authors (1993). Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 67, 6424-6431.
26. Ordóñez, R. M., Espinosa, A. M., Sánchez-González, D. J., Armendáriz-Borunda, J. & Berumen, J. (2004). Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6 /E7 oncogene transcription. J Gen Virol 85, 1433-1444.
27. Pim, D. & Banks, L. (1999). HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18, 7403-7408.
28. Pim, D., Storey, A., Thomas, M., Massimi, P. & Banks, L. (1994). Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 9, 1869-1876.
29. Pim, D., Massimi, P. & Banks, L. (1997). Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15, 257-264.
30. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
31. Schlecht, N. F., Kulaga, S., Robitaille, J. & 8 other authors (2001). Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286, 3106-3114.
32. Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M. & Fornace, A. J., Jr (1995). Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10, 1053-1059.
33. Stacey, S. N., Jordan, D., Snijders, P. J. F., Mackett, M., Walboomers, J. M. M. & Arrand, J. R. (1995). Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J Virol 69, 7023-7031.
34. Stöppler, M. C., Ching, K., Stöppler, H., Clancy, K., Schlegel, R. & Icenogle, J. (1996). Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 70, 6987-6993.
35. Walboomers, J. M. M., Jacobs, M. V., Manos, M. M. & 7 other authors (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-19.
36. Werness, B. A., Levine, A. J. & Howley, P. M. (1990). Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 248, 76-79.
37. WHO (2004). The World Helath Report 2004: Changing History, Statistical Annex. Geneva: World Health Organization (http://whqlibdoc.who.int/whr/2004/924156265X.pdf).
38. Xi, L. F., Koutsky, L. A., Galloway, D. A., Kuypers, J., Hughes, J. P., Wheeler, C. M., Holmes, K. K. & Kiviat, N. B. (1997). Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 89, 796-802.
39. Zehbe, I., Wilander, E., Delius, H. & Tommasino, M. (1998). Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58, 829-833.
40. Zhang, H.-G., Wang, J., Yang, X., Hsu, H.-C. & Mountz, J. D. (2004). Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23, 2009-2015.
41. zur Hausen, H. (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2, 342-350.